Patient advocacy groups (PAGs) can provide a valuable avenue to recruit patients for clinical trials. Such groups are mobilized to promote education, awareness and research for their constituents.
Many pharma companies have relationships with PAGs, but have had mixed success in leveraging them for clinical trial recruitment. To effectively engage, pharma must work to develop committed, long-term and mutually beneficial relationships with PAGs. Consider the following:
This framework should help create rich relationships with PAGs that move all parties toward the shared goal of providing better treatment options for patients.
Written by Guest Writer Tammy Russo. Russo, vice president and advocacy relations practice lead at Continuum Clinical, has built advocacy offerings at Astellas, Shire and Lundbeck, leveraging a background in healthcare marketing, integrated communications and public relations. Her work includes identification of, outreach to and relationship management relevant to key patient advocacy groups and medical societies. She has led unbranded patient advocacy education campaigns, aligned with co-marketing partners, to translate clinical and commercial messaging for patient advocates, patients, care partners and caregivers.
This article was reprinted from Volume 22, Issue 12, of The CenterWatch Monthly, an industry leading publication providing hard-hitting, authoritative business and financial coverage of the clinical research space. The Action Items section features short columns focusing on actionable or how-to advice from clinical trial professionals. To submit an Action Item, please contact firstname.lastname@example.org. Subscribe >>